Findings

What do systematic reviews say?

11 questions · 11 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 1 · 9.1%Very low 2 · 18.2%Low 3 · 27.3%Moderate 5 · 45.5%High 0 · 0%

Oral creatine vs placebo

Adverse events related to treatment · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Low

Oral olesoxime vs placebo

Adverse events related to treatment · non‐ambulatory children and adolescents with SMA types II and III

Oral olesoxime probably leads to lower adverse events related to treatment compared with placebo (moderate certainty).

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
RR 0.95 [0.91, 0.99]
1 study · 165 participants
Moderate

Oral gabapentin vs placebo

Adverse events related to treatment · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 65 participants
Low

Oral hydroxyurea vs placebo

Adverse events related to treatment · children and adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 57 participants
Moderate

Oral valproic acid vs placebo

Adverse events related to treatment · ambulatory adults with SMA type III

Oral valproic acid showed no clear difference in adverse events related to treatment compared with placebo (low certainty).

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
RR 0.8 [0.44, 1.44]
33 participants
Low

Oral phenylbutyrate vs placebo

Adverse events related to treatment · children with SMA type II

Oral phenylbutyrate probably leads to higher adverse events related to treatment compared with placebo (moderate certainty).

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
RR 3.1 [1.25, 7.84]
1 study · 107 participants
Moderate

Oral valproic acid plus acetyl‐L‐carnitine vs placebo

Adverse events related to treatment · non‐ambulatory children with SMA types II and III

Oral valproic acid plus acetyl‐L‐carnitine showed no clear difference in adverse events related to treatment compared with placebo (moderate certainty).

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
RR 1.32 [0.92, 1.89]
1 study · 61 participants
Moderate

Oral azithromycin vs placebo

Adverse events: number of mild treatment‐related adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 748 participants
Moderate

Intramuscular ceftriaxone vs oral cefixime

Adverse events including treatment‐related adverse events · pregnant women with gonorrhoea infection

1 finding from 1 review

Antibiotics for treating gonorrhoea in pregnancy 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 95 participants
GRADE not reported

Intramuscular ceftriaxone vs oral amoxicillin plus oral probenecid

Adverse events including treatment‐related adverse events · pregnant women with gonorrhoea infection

It is very uncertain whether intramuscular ceftriaxone changes adverse events including treatment‐related adverse events compared with oral amoxicillin plus oral probenecid (very low certainty).

1 finding from 1 review

Antibiotics for treating gonorrhoea in pregnancy 2018 · Cochrane Headline outcomes only
RR 0.33 [0.01, 8.07]
1 study · 168 participants
Very low

Summary of findings ‐ nebulised azithromycin vs azithromycin

Adverse events: number of treatment‐related adverse events · children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Very low